Keeping Up With Lucentis: Regeneron’s Eylea Adds Diabetic Retinopathy Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval of supplemental indication for aflibercept brings intravitreal injection’s label in line with that of Genentech’s ranibizumab; Eylea’s dosing advantage and positive data from a recent head-to-head study are likely to put more pressure on Lucentis sales.